Research programme: autoimmune disease therapy - Resolve Therapeutics

Drug Profile

Research programme: autoimmune disease therapy - Resolve Therapeutics

Alternative Names: RSLV-125; RSLV-133

Latest Information Update: 18 Mar 2014

Price : $50

At a glance

  • Originator Washington University
  • Developer Resolve Therapeutics
  • Class Biological proteins; Recombinant fusion proteins
  • Mechanism of Action Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Systemic lupus erythematosus

Most Recent Events

  • 17 Mar 2014 RSVL 132 has entered clinical development for for Systemic lupus erythematosus in USA
  • 01 Mar 2013 Resolve Therapeutics and Takeda agree to co-develop autoimmune disease therapeutics in USA for systemic lupus erythematosus
  • 02 Nov 2012 IND-enabling preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top